# UNIVERSITY<sup>OF</sup> BIRMINGHAM University of Birmingham Research at Birmingham

## A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus

Botfield, Hannah F; Uldall, Maria S; Westgate, Connar S J; Mitchell, James L; Hagen, Snorre M; Gonzalez, Ana Maria; Hodson, David J; Jensen, Rigmor H; Sinclair, Alexandra J

DOI: 10.1126/scitranslmed.aan0972

License: Other (please specify with Rights Statement)

Document Version Peer reviewed version

Citation for published version (Harvard):

Botfield, HF, Uldall, MS, Westgate, CSJ, Mitchell, JL, Hagen, SM, Gonzalez, AM, Hodson, DJ, Jensen, RH & Sinclair, AJ 2017, 'A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus', *Science Translational Medicine*, vol. 9, no. 404, eaan0972. https://doi.org/10.1126/scitranslmed.aan0972

Link to publication on Research at Birmingham portal

#### **Publisher Rights Statement:**

This is the author's version of the work. It is posted here by permission of the AAAS for personal use, not for redistribution. The definitive version was published in Science Translational Medicine, Volume 9 on 23rd August 2017, DOI: 10.1126/scitranslmed.aan0972

#### **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

•Users may freely distribute the URL that is used to identify this publication.

•Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.

•User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?) •Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

#### Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

#### **1** Supplementary Information

- 2
- 3

## 4 Supplementary Materials and Methods

## 5 **Reagents**

Exendin-4 (GLP-1R agonist), exendin-\_9-39 (GLP-1R antagonist), ouabain (specific Na<sup>+</sup> K<sup>+</sup> 6 ATPase inhibitor), 3-Isobutyl-1-methylxanthine (IBMX; phosphodiesterase inhibitor) and 7 8 Forskolin (adenylate cyclase activator) were purchased from Sigma-Aldrich. For the in vivo 9 studies exendin 9-39 was purchased from Cohesion Biosciences (CCP1199) and Abcam (ab141101). Fluorescently tagged exendin-4 (FLEX) was purchased from AnaSpec (AS-10 11 63899). The myristoylated PKA inhibitor (PKI)-(14-22)-amide was purchased from Merck 12 Chemicals. Mouse monoclonal antibody against human GLP-1R protein was purchased from the Developmental Studies Hybridoma Bank (Iowa; Mab 3F52, deposited by Knudsen, L.B.). 13 Primary antibodies for choroid plexus epithelial (CPe) cell characterization included antibodies 14 against transthyretin (TTR; sheep, ab9015, Abcam), Na<sup>+</sup> K<sup>+</sup> ATPase (rabbit, ab76020, Abcam; 15 mouse, 05-369, Millipore), zona occludens-1 (ZO-1; rabbit, 61-7300, Life Technologies), 16 aquaporin 1 (AQP1; rabbit, AB3065, Abcam; rabbit, AB2219, Millipore) and β-actin (mouse, 17 A5441, Sigma Aldrich). For immunohistochemistry, the Alexa Fluor<sup>®</sup> labelled secondary 18 antibodies were purchased from Life Technologies and for western blot, HRP-conjugated 19 20 secondary antibodies were bought from Cell Signaling Technology. Cell culture reagents were from Life Technologies or Sigma-Aldrich and unless specified all other chemicals were 21 purchased from Sigma-Aldrich. For surgical procedures the midazolam was purchased from B. 22 23 Braun and the fluanisone and fentanylcitrate from the Danish pharmacy supply.

24

#### 25 In vitro experiments

26 Whole Choroid plexus. The choroid plexus from the lateral ventricles were dissected and placed in artificial CSF (aCSF; 118mM NaCl, 22mM NaHCO<sub>3</sub>, 1.45mM K<sub>2</sub>HPO<sub>4</sub>, 1mM 27 MgSO<sub>4</sub>, 1mM CaCl<sub>2</sub> and 10mM glucose). To evaluate the effects of exendin-4 ondemonstrate 28 29 the presence of the GLP-1R localisation within the cellin the choroid plexus, whole choroid plexus was incubated with aCSF containing (a) 1µM FLEX for 15 and 30 minutes or (b) 1µM 30 exendin 9-39 for 10 minutes followed by 1µM FLEX for 30 minutes. 100nM Exendin 9-39 for 31 15 minutes followed by 100nM exendin-4 for 30 minutes or 100nM exendin-4 only for 15 and 32 30 minutes. Whole choroid plexus was then fixed and visualized under a Zeiss LSM 510 UV-33 34 confocal microscope (Carl Zeiss)stained following the protocol described below. To determine the effects of exendin-4 on GLP-1R mRNA expression the choroid plexus was incubated with 35 aCSF containing 100nM exendin-4 for 3 and 6 hours, immediately frozen in liquid nitrogen 36 and stored at -80°C. 37

38

Primary CPe cell culture. Choroid plexus tissue from lateral and fourth ventricles were 39 dissected and incubated with 0.25% trypsin solution for 2.5 hours at 4°C followed by 30 40 minutes at 37°C. Trypsin digestion was stopped by the addition of newborn calf serum and the 41 cell suspension was centrifuged at 20g for 10 minutes. Cells were resuspended in DMEM/F12 42 supplemented with 10% FBS, 1% penicillin/streptomycin, 4mM L-glutamine, 200ng/ml 43 hydrocortisone, 5ng/ml sodium selenite and 10ng/ml EGF. 20µM cytosine arabinoside was 44 used for the first 4 days in culture to limit the growth of fibroblasts (53). Initially the cells were 45 seeded onto a laminin coated 6 well plate and allowed to grow for 2 days before being 46 transferred to laminin coated 96 well plates or 12 well inserts (Greiner Bio-One Ltd). On day 4 47 the media was replaced with DMEM/F12 supplemented with 10% FBS and 1% 48 penicillin/streptomycin and changed every 2-3 days. After reaching confluency, CPe cells were 49 serum deprived for 3 days prior to the beginning of the studies (between days 10-14). 50

51

**Immunofluorescent staining.** For staining of rat brain tissue sections, rats were euthanized 52 with rising CO<sub>2</sub> and immediately perfused transcardially with 10mM PBS, pH 7.4 (PBS) 53 followed by 4% paraformaldehyde (PFA; Alfa Aesar) in PBS. Brains were postfixed overnight 54 at 4°C, cryoprotected by sequential immersion in 10%, 20% and 30% sucrose in PBS at 4°C, 55 embedded in OCT (Fisher Scientific), and 15-µm-thick coronal sections cut on a cryostat 56 57 (Bright Instruments), mounted on charged microscope slides and stored at -20<sup>o</sup>C until use. Sections were first washed in PBST (PBS containing 0.3% Tween20), blocked in PBST 58 59 containing 2% bovine serum albumin (BSA) and 15% normal goat serum (NGS) for 20 minutes at room temperature, and then incubated with the primary antibody (PBST with 2% 60 BSA) at 4°C overnight. After washing in PBST, sections were incubated for 1 hour at room 61 temperature in the dark with the appropriate Alexa Fluor 488 labelled secondary antibody 62 diluted in PBST containing 2% BSA and 1.5% NGS. Finally, sections were washed in PBST 63 64 before mounting in Vectashield containing the nuclear stain DAPI (Vector Laboratories).

For fluorescence labelling of CPe cells, samples were first fixed in PBS containing 2% PFA and 2% glucose for 20 minutes at room temperature, washed in PBS and then permeabilized with methanol for 6 minutes at room temperature. The cells were stained using the same technique described above except that PBST was substituted with PBS.

69 Stained cells and sections were viewed under a Zeiss LSM 510 UV-confocal
70 microscope (Carl Zeiss) and multiple Z-stack images were taken.

71

**Immunoperoxidase staining.** For staining of paraffin-embedded human choroid plexus, the sections were dewaxed and dehydrated to distilled water. Sections were treated for 30 minutes in Tris-EDTA buffer (pH 9.0) at 95°C in a waterbath for antigen retrieval. The sections were then cooled in PBST before incubation with 1%  $H_2O_2$  (70% methanol in PBS) for 30 minutes 76 to inhibit endogenous peroxidase. Sections were washed in PBST, blocked in PBST containing 77 2% BSA and 15% normal serum for 1 hour at room temperature, and then incubated in primary antibody solution at 4°C overnight. Sections were again washed in PBST before incubation in 78 79 biotinylated secondary antibody solution (Vector Laboratories) for 30 minutes at room temperature. Sections were washed in PBST and then incubated for 30 minutes at room 80 81 temperature in Avidin/Biotin Complex (ABC; Vectastain Elite ABC kit, Vector Laboratories) following the manufacturer's instructions. After rinsing in PBST, sections were treated with 82 3'3 diaminobenzidine (DAB) substrate (Vector Laboratories), washed in distilled water, 83 84 counterstained with haematoxylin, washed in running water before dehydration, cleared in xylene and mounted in Vectamount medium (Vector Laboratories). 85

86

87 Quantitative polymerase chain reaction (qPCR). For qPCR studies the choroid plexus was dissected, immediately frozen in liquid nitrogen and stored at -80°C. Primary cultures of CPe 88 cells were grown on 12 well inserts until confluency. Total RNA was extracted using the 89 GenElute mammalian total RNA extraction kit and carried out according to the manufacturer's 90 instructions. RNA was reverse transcribed to complementary DNA (cDNA) using a high 91 capacity reverse transcription kit (Life Technologies) or iScript cDNA synthesis kit (Biorad) 92 according to the manufacturer's protocol. Taqman Gene Expression Assays (Life 93 Technologies) were used to assess the expression of GLP-1R (assay number Rn00562406 m1 94 95 and Hs00157705\_m1), Na<sup>+</sup> K<sup>+</sup> ATPase (assay number Rn01533986\_m1), AQP1 (assay number Rn00562834\_m1) and NHE1 (assay number Rn00561924\_m1). The 18S ribosomal 96 subunit was used as an endogenous reference (4319413E) and samples were run in triplicate. 97 98 The cycle number at which the particular sample crossed that threshold (Ct) was used to determine the levels of gene expression and  $\Delta Ct$  was calculated as the difference between the 99 Ct (gene of interest) and the Ct (endogenous reference). 100

101

Western blot. The choroid plexus was dissected, immediately frozen in liquid nitrogen and 102 stored at -80°C. Tissues were homogenised in ice cold RIPA lysis buffer and centrifuged at 103 13,000g to remove cell debris. Tissue lysates (10µg protein) were separated on a 4-12% tris-104 glycine gel. The proteins were transferred onto a polyvinylidene difluoride membrane and 105 subsequently blocked with 5% skimmed milk powder in TBST (TBS pH 7.4 with 0.5% 106 107 Tween20) for 1 hour at room temperature before incubation with the primary antibody diluted in milk/TBST overnight at 4°C. After washing in TBST the membranes were incubated with 108 109 HRP-conjugated secondary antibody diluted in milk/TBST for 1 hour at room temperature. The bands were detected using ECL reagents (Amersham) and developed onto film. 110

111

cAMP assay. The effect of exendin-4 on the downstream GLP-1R signaling pathway was 112 assessed by measuring the levels of cAMP in CPe cells using two different techniques. The 113 114 first assay was the Amersham cAMP Biotrak Enzyme immunoassay System (RPN 225, GE Healthcare Life Sciences). CPe cells were grown on a 96 well plate (described previously) and, 115 on the day of the experiment, incubated in aCSF supplemented with 1mM IBMX containing; 116 aCSF only (n=8), 100nM exendin-4 (n=8) or 100nM Forskolin (positive control; n=5) for 30 117 minutes at 37°C. The cells were subsequently lysed and cAMP detected according to the 118 119 manufacturer's instructions. The second assay was the LANCE® (Lanthanide chelate excite) cAMP 384 kit (PerkinElmer). CPe cells were grown in flasks and then trypsinized to form a 120 single cell suspension. The cells were incubated in stimulation buffer (PBS with 5.5mM 121 glucose, 0.1% BSA and 0.5mM IBMX) containing; 1nM (n=5), 10nM (n=6) and 100nM 122 exendin-4 (n=5), with and without 1µM exendin 9-39 (n=6, n=5 and n=5 respectively), and 123 forskolin (n=6) as a positive control. cAMP was then detected according to the manufacturer's 124 instructions. 125

126

 $Na^+ K^+ ATP$  as activity assay. The effect of exendin-4 on  $Na^+ K^+ ATP$  as activity in the 127 choroid plexus was evaluated by the colorimetric measurement of phosphate released from 128 ATP hydrolysis with the use of a phosphate assay kit (ab65622, Abcam); with  $Na^+ K^+ ATP$  as 129 activity being defined as the portion of phosphate produced that is sensitive to ouabain. CPe 130 cells were incubated with aCSF for 1 hour at 37<sup>o</sup>C before incubation in aCSF containing; 131 100nM exendin-4 (n=7), 5µM PKI-16-22-amide (n=8), 100nM exendin-4 + 5µM PKI-16-22-132 amide (n=8); in the presence and absence of 1mM ouabain for 30 minutes at 37°C. The cells 133 134 were then lysed on ice and spun at 13,000g to remove cell debris. Phosphate was measured as per the manufacturer's instructions. Briefly the reaction mix was added to the samples and 135 incubated at room temperature for 60 minutes before the plate was read at 690nm. Na<sup>+</sup> K<sup>+</sup> 136 ATPase activity was calculated as the difference between the amount of phosphate produced in 137 the presence and absence of ouabain for each treatment. 138

139

#### 140 In vivo experiments

Epidural ICP probe implantation. Implantation of an epidural ICP probe and its validation 141 were recently published as a methodological work that contains all technical and surgical detail 142 143 (54). The rats were anaesthetized (2.7ml/kg subcutaneous injection containing 1.25mg/ml midazolam, 2.5mg/ml fluanisone and 0.079mg/ml fentanylcitrate), placed in a stereotactic 144 frame (David Kopf Instruments) and a 2cm-midline incision was performed on top of the skull 145 and the bone was exposed by retracting the skin and soft tissue. A dental drill was used to make 146 4 burr holes in the skull; one large hole was carefully drilled to expose the dura mater enabling 147 placement of the epidural ICP probe (C313G-3UP, PlasticsOne), with the cannula cut to be 148 level with the base of the pedestal. The other 3 smaller holes were used to fit anchoring screws 149 to the skull. The epidural pressure bolt and the anchoring screws were placed and aligned with 150

the interior surface of the skull and secured using dental resin-cement (Clearfil SA Cement, RH
Dental). The epidural ICP probe and the transducer (DTX-Plus<sup>TM</sup>, Argon Medical Devices)
were then connected by a polyethylene tube filled with sterile water, ensuring the absence of
air bubbles. The pressure signal was visualized and recorded using Perisoft v.2.5.5 (Perimed).
Correct ICP signal was confirmed by the transient elevation of ICP after jugular vein
compression. When the ICP recording procedure was completed the epidural pressure cannula
was closed with a bite proof cap (303DCFTX2, PlasticsOne) and the rat allowed to recover.

There was one modification with the epidural ICP probe implantation in the hydrocephalic rats; before the epidural pressure bolt was placed on the dura, a small hole (1mm in diameter) was made with forceps in the dura.

161

## 162 Intracerebroventricular (ICV) injection

163 During the epidural ICP probe surgery, animals receiving ICV treatments also had an ICV 164 cannula implanted at the same time. An additional burr hole was made 0.8mm posterior and 165 1.6mm lateral to Bregma. The cannula was inserted into the left lateral ventricle, fixed with 166 dental resin-cement and closed by a cap with a dummy cannula to maintain patency. For the 167 ICV injection rats were anesthetized and connected to the transducer to measure ICP. Once a 168 stable baseline had been established a 5 $\mu$ l Hamilton syringe connected via tubing to an internal 169 cannula was used for the ICV injection.

170

#### 171 Osmotic pump implantation

Osmotic pumps (model 1003D, Alzet, Durect Corporation, California, USA) were prepared under sterile conditions and primed in sterile saline overnight at 37°C to allow prompt delivery after implantation. The ICV cannula (brain infusion kit 1, Alzet) was set to 4mm and attached to the pump via 5cm catheter tubing containing saline. The osmotic pump was filled with either 176 saline or 4mg/ml exendin 9-39, thus the infusion rate was  $4\mu g/\mu l/hr$  (around 100 $\mu g$  per day). 177 The fluid in the pump and the fluid in the catheter tubing were separated by an air bubble to 178 delay the start of exendin 9-39 until implantation.

For implantation of the osmotic pump, the head of anaesthetized rat was fixed in a stereotactic frame, the dorsal skull was exposed and a burr hole sited in the parietal bone 0.8mm posterior and 1.6mm lateral to Bregma. The ICV cannula was inserted into the left lateral ventricle and fixed in place with glue to 2 stabilising screws (PlasticsOne), and the osmotic pump was implanted subcutaneously in the neck region. The epidural ICP probe was then implanted as above.

185


## 186 Induction of hydrocephalus

187 We used the kaolin model of hydrocephalus as our model of raised ICP. The rats were anaesthetized and the head fixed in a stereotactic frame with the neck flexed down in a 90 188 degree angle to horizontal and secured in this position. A mark was made on the skin above the 189 dorsal atlanto-occipital membrane between the skull and the first cervical spinosus. The 190 percutaneous injection was performed using an insulin syringe with a 30 gauge needle, which 191 was slowly advanced in a vertical direction until there was a loss of resistance and 80 µL of 192 sterile kaolin suspension (0.250 mg/mL in Ringer's lactate solution - 1.4mM Ca<sup>2+</sup>, 4mM K<sup>+</sup>, 193 130mM Na<sup>+</sup>, 109mM Cl<sup>-</sup>, 28mM lactate) injected gradually (8.5 µL/s). Following the injection 194 195 the neck was extended, the head released from the stereotactic frame and the animal allowed to recover. 196

197

Blood and electrolyte Measurements. Blood and CSF pH and electrolytes were measured
immediately using an ABL80 FLEX blood gas analyzer (Radiometer Medical ApS).

200



201

202 Fig. S1. Characterisation of primary rat choroid plexus epithelial (CPe) cells in vivo and in vitro. (A) The identity of CPe cells in culture was determined by immunohistochemistry 203 using antibodies against: (1) transthyretin (TTR), a CPe cell marker; (2) Na<sup>+</sup> K<sup>+</sup> ATPase, ion 204 pump involved in actively moving  $Na^+$  out of the CPe cells and into the CSF, (3) zona 205 occludens-1 (ZO-1), a tight junction protein; and (4) aquaporin 1 (AQP1), the most prominent 206 water channel in the choroid plexus. TTR staining (green) was observed in the cytoplasm of 207 208 the CPe cells; ZO-1 (green) was localised at the interface between the cells indicating the presence of tight junctions; Na<sup>+</sup> K<sup>+</sup> ATPase and AQP1 (green) were present on the apical 209 surface of the epithelial cells indicating the polarisation of the cells in vitro and in vivo. (B) 210 The histogram represents the fold change in *Glp-1r* mRNA from whole choroid plexus + SEM 211 (choroid plexus n=3; CPe cells n=3), demonstrating *Glp-1r* mRNA is present in both the CPe 212 213 cells and whole choroid plexus. DAPI (blue) was used as a nuclear marker, scale bar - 50µm.




Fig. S2. Suggested route for GLP-1 action at the choroid plexus. (A) Under physiological 215 conditions, GLP-1 is secreted by L cells in response to nutrients in the gut and then enters the 216 bloodstream or activates the vagus nerve. Therapeutic administration of GLP-1 mimetics is via 217 a subcutaneous injection. Once in the bloodstream, GLP-1 could bind to GLP-1 receptors 218 (GLP-1Rs) on the basal surface of the choroid plexus epithelial (CPe) cells or could cross the 219 blood brain barrier and enter the CSF. Alternatively, the vagus nerve could stimulate GLP-1 220 221 production at the nucleus tractus solitarius (NTS), which has fibres projecting to the hypothalamus (H) adjacent to the CSF. This allows GLP-1 secretion into the CSF, from where 222 it can bind with GLP-1Rs on the apical surface of the CPe cells. (B) In the kidney proximal 223 224 tubule cells, the binding of GLP-1 to its receptor stimulates the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP) by adenylate cyclase (AC) 225 through  $G\alpha_s$  protein subunit. cAMP activates protein kinase A (PKA), which phosphorylates 226 the  $Na^+ H^+$  exchanger resulting in its inhibition, thus preventing  $Na^+$  reabsorption. (C) We 227 hypothesize that activation of GLP-1R on choroid plexus epithelial cells stimulates AC, which 228 229 converts ATP to cAMP. cAMP subsequently activates PKA which could phosphorylate either the Na<sup>+</sup> H<sup>+</sup> exchanger or the Na<sup>+</sup> K<sup>+</sup> ATPase, reducing Na<sup>+</sup> transport from blood into the CSF. 230 This would decrease CSF production and potentially reduce ICP. 231